Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Inventory (2017 - 2025)

Historic Inventory for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.5 million.

  • Puma Biotechnology's Inventory rose 25450.8% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 25450.8%. This contributed to the annual value of $8.7 million for FY2024, which is 2322.03% up from last year.
  • Latest data reveals that Puma Biotechnology reported Inventory of $9.5 million as of Q3 2025, which was up 25450.8% from $8.6 million recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Inventory registered a high of $9.5 million during Q3 2025, and its lowest value of $2.7 million during Q3 2024.
  • Its 5-year average for Inventory is $7.0 million, with a median of $7.2 million in 2021.
  • As far as peak fluctuations go, Puma Biotechnology's Inventory crashed by 5293.19% in 2024, and later surged by 25450.8% in 2025.
  • Puma Biotechnology's Inventory (Quarter) stood at $7.1 million in 2021, then tumbled by 36.33% to $4.5 million in 2022, then skyrocketed by 56.43% to $7.1 million in 2023, then rose by 23.22% to $8.7 million in 2024, then grew by 8.62% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, $8.6 million for Q2 2025, and $8.8 million during Q1 2025.